In ischemic stroke patients with low LDL levels (<30-50 mg/dl), would you consider lowering LDL levels to lower values without concern for any side effects?

If LDL levels are already below 70, I don’t target a lower goal. The SPARCL trial showed that reducing LDL to this range has an NNT of about 45 to prevent one stroke, which I find to be modest at best. From my perspective, lowering LDL further (<30-50 range) shifts the focus to treating a number rather than the patient.

For patients where dyslipidemia is a factor in secondary prevention, emphasizing lifestyle modifications such as diet, exercise, and smoking cessation is key, as these can also help raise HDL, which I find more beneficial overall. There is ongoing research into targeting Lipoprotein(a) and Apolipoprotein(B), but nothing definitive that I’m aware of.

Additionally, there’s a theoretical concern that very low LDL levels could imp...

In my opinion, the best answer to this question is that we probably don't know the answer yet. While the SPARCL trial was helpful, it didn't even include this population in the study as patients had to have an LDL of at least 100 mg/dL.

Assuming the lipid panel was obtained correctly, I think one can extrapolate an answer based on cardiology and general lipid management data. Per the European Society of Cardiology/European Atherosclerotic Society (ESC/EAS), a patient should target LDL <70% and ≥50% LDL reduction from baseline if they are in the high-risk group. A history of an ASCVD event (TIA, stroke) is considered a high-risk factor. Very high-risk patients should aim for ≥50% LDL reduction from baseline and LDL <55 mg/dL. An even lower LD...

There is no evidence for statin therapy for patients with ischemic stroke and LDL<70. The SPARCL trial showed atorvastatin to be beneficial in ischemic stroke patients, but the LDL had to be >100.

I agree with all the prior answers. While we do not have robust data but mostly smaller studies - in patients with atherosclerotic disease, adding a statin can help with the reduction of plaque inflammation and may over time reduce the intimal thickness due to atherosclerotic disease. This benefit was regardless of LDL levels in some studies. This may be due to the reduction of plaque inflammation which increases the size and vulnerability of the plaque, increasing chances of rupture. So in these patients, there may be some benefit regardless of LDL levels. Also, currently, there is no substantial evidence that low LDL definitely causes ICH, however SATURN trial will help give us some more definitive answers.

One should look at the mechanism of the stroke more closely and consider the full history of research about cholesterol as being the “bad guy culprit in all things vascular” mentality. The dogma was further reinforced by select scientists and big industry, all of which had a very influential role in funding groups that create AHA position statements.

When bringing up statins, I also like to mention to patients the counter evidence, the reality of how long they must be on the statin to get any of the major claimed benefits, the absolute risk reduction, the NNT, and definitely the risk of diabetes.